---
title: "Lilly Targets Early 2027 Filing for Next Obesity Drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293649982.md"
description: "Eli Lilly reported positive Phase 3 trial results for its obesity drug retatrutide, confirming a BLA submission to the FDA in Q1 2027. The triple-hormone agonist demonstrated significant weight loss (22.6% in severe obesity, 20.8% in type 2 diabetes) but showed a 12% higher risk of severe cardiovascular events compared to placebo. Shares dipped slightly premarket following the announcement."
datetime: "2026-07-23T17:13:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293649982.md)
  - [en](https://longbridge.com/en/news/293649982.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293649982.md)
---

# Lilly Targets Early 2027 Filing for Next Obesity Drug

Eli Lilly fell 0.35% in premarket after reporting positive results from two further Phase 3 trials of retatrutide and confirming it will submit a biologics license application to the FDA in the first quarter of 2027. The drug targets three metabolic hormones, GLP-1, GIP and glucagon, against two for Lilly's current Zepbound and one for Novo Nordisk's Wegovy.

In an 80-week study of adults with severe obesity and established heart disease, the highest weekly dose produced average weight loss of 22.6%. A separate 80-week trial in overweight or obese patients with type 2 diabetes showed 20.8% weight loss and lowered A1C levels by 1.6%. Nausea and diarrhea were the most common side effects in both.

Major cardiovascular events occurred less often than expected in both the treatment and placebo arms, but on the three most severe endpoints, heart attack, stroke and death, retatrutide patients carried a 12% higher risk than placebo. Executive vice president Kenneth Custer said the drug has shown "powerful efficacy" across five positive Phase 3 studies.

### Related Stocks

- [LLY.US](https://longbridge.com/en/quote/LLY.US.md)
- [LLYZ.US](https://longbridge.com/en/quote/LLYZ.US.md)
- [ELIL.US](https://longbridge.com/en/quote/ELIL.US.md)
- [LLYX.US](https://longbridge.com/en/quote/LLYX.US.md)
- [ELIS.US](https://longbridge.com/en/quote/ELIS.US.md)
- [NVO.US](https://longbridge.com/en/quote/NVO.US.md)

## Related News & Research

- [Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application](https://longbridge.com/en/news/293600518.md)
- [Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials](https://longbridge.com/en/news/293607076.md)
- [Eli Lilly's Retatrutide Meets Primary Endpoint In Phase 3 TRIUMPH-2 And TRIUMPH-3 Trials](https://longbridge.com/en/news/293605576.md)
- [First Trust Advisors LP Acquires 1,305 Shares of Eli Lilly and Company $LLY](https://longbridge.com/en/news/293719299.md)
- [HBM Healthcare swings to CHF 238 million Q1 FY27 profit; NAV per share rises 13%](https://longbridge.com/en/news/293701781.md)